Safety and Efficacy of Individual Batches of ATG-F in Kidney Transplant Recipients: Multicentre, Prospective, Observational Study

Trial Profile

Safety and Efficacy of Individual Batches of ATG-F in Kidney Transplant Recipients: Multicentre, Prospective, Observational Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 09 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 15 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Jan 2018 Planned End Date changed from 31 Mar 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top